Key Takeaways
- A dental partnership transition follows seven structured phases that help owners influence valuation, create buyer competition, and protect legacy.
- Knowing the timeline and valuation methods, whether doctor-to-doctor or private equity, can help sellers improve outcomes and reduce re-trade risk.
- Professional sell-side representation, such as McLerran & Associates, often delivers about 30% higher valuations and an 85–90% close rate compared to DIY sales.
- Key phases include pre-planning valuation, deal-team assembly, confidential marketing, diligence defense, staff communication, and post-close integration.
- Owners ready to explore their options can contact McLerran & Associates for a confidential discovery call.
Dental Partnership Transition Timeline Steps
The seven phases below apply to both major exit paths: a doctor-to-doctor partnership or vest-out, and a private equity affiliation. The two paths share the same sequence, yet they differ in duration, valuation method, post-close structure, and close rate. The table below provides a side-by-side comparison before the steps are examined in detail.
| Dimension | Doctor-to-Doctor Partnership / Vest-Out | Private Equity Affiliation |
|---|---|---|
| Typical total timeline | 60–120 days from listing to close | 3-6 months of active process from engagement to close |
| Primary valuation method | Percentage of trailing 12-month collections (commonly 60–85%) | Multiple of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) |
| Post-close structure | ~4–8 week work-back (walk-away) or multi-year vest-out partnership | Minimum 5-year employment agreement, up to ~40% of deal value in equity |
| DIY close rate | ~15–20% (McLerran & Associates internal data) | ~15–20% (McLerran & Associates internal data) |
| Advised close rate | ~85–90% (McLerran & Associates internal data) | ~85–90% (McLerran & Associates internal data) |
Step 1: Pre-Planning Valuation Built for Diligence
Every successful transition starts with a defensible number. A valuation that cannot withstand buyer scrutiny quietly determines what the owner takes home, and a weak one often gets re-traded during diligence. McLerran & Associates builds a CPA-led EBITDA analysis from the ground up, remotely accessing practice management software, cross-referencing production data against financials, and unpacking every discretionary, personal, and non-recurring expense to arrive at true profitability.
For doctor-to-doctor deals, value is expressed as a percentage of trailing collections. For private equity deals, it is expressed as a multiple of adjusted EBITDA. Owners weighing both paths receive a side-by-side valuation that quantifies their worth in each market. Practices showing three consecutive years of revenue growth typically receive stronger offers, so early preparation can directly strengthen both valuation and negotiating position.
Across more than 10,000 practices evaluated and roughly 2,000 closed sales, McLerran & Associates has refined this analysis into diligence-grade work. Buyer accountants can question the numbers, yet they rarely dismantle them.
Step 2: Assembling a Dental-Specific Deal Team
A practice sale is often one of the most complex financial transactions a dentist will navigate. The deal team assembled at this stage can influence whether the transaction closes at full value or stalls. A seller’s professional advisory team can include a practice broker or transition advisor, CPA, dental-practice-experienced attorney, and financial planner to handle pricing, confidential marketing, tax structuring, purchase agreements, and retirement alignment.
McLerran & Associates serves as the sell-side advisor and advocate, effectively the quarterback of the entire process. With over 100 years of collective dental-industry experience drawn from former investment bankers, practice-finance lenders, DSO buyers, CPAs, and advisors, the firm controls the narrative around the practice’s value from the first conversation to the final signature. The team makes introductions to attorneys, lenders, and other specialists while staying focused on its core mandate: improving the owner’s outcome.
Because McLerran works both the private-buyer and DSO markets in roughly equal measure, an approximately 50/50 split, owners receive guidance that reflects their goals rather than a recommendation shaped by a narrow buyer list.
Connect with McLerran & Associates to meet the team that can advocate for your transition.
Step 3: Comparing Partnership and Private Equity Paths
Choosing between a doctor-to-doctor partnership or vest-out and a private equity affiliation can be one of the most consequential strategic decisions in the entire dental partnership transition timeline. The right answer often depends on practice size, profitability, and the owner’s personal “why.”
Smaller premier practices, commonly in the $1–1.5 million revenue range, often fit a doctor-to-doctor sale. Larger practices, particularly those above $1.5 million in revenue, can attract private equity interest. Owners in the $1.5–3 million revenue range can often pursue either path, and they benefit from a side-by-side comparison that quantifies the real after-tax outcome across both options over 3-, 5-, 7-, and 10-year horizons.
The private equity market remains active, with 69% of DSOs expecting to increase acquisition activity in 2026 as sponsors push for growth. This sustained demand has contributed to notable industry consolidation in recent years. At the same time, some heavily leveraged private equity groups have faced financial restructuring challenges, which highlights why careful buyer vetting can matter as much as finding buyers.
McLerran’s competitive process, which produces the 30% valuation premium mentioned earlier, works by generating around 10 offers per listing and creating real bidding tension. That competition can move both price and terms in the seller’s favor.
Step 4: Running a Confidential, Competitive Marketing Process
Once the valuation is complete and the path is chosen, the practice quietly goes to market. McLerran builds a detailed marketing profile and, for private equity transactions, a virtual data room containing everything worth showcasing to qualified buyers. For doctor-to-doctor deals, the firm draws on the largest premier private-buyer pool in the country, marketing through direct mail, geofencing, study-club relationships, and dental organization networks.
The private equity bid process typically runs about 45–60 days and often generates around 10 offers from a vetted, pre-qualified pool of buyers. Private equity groups known for poor post-close environments are blacklisted before the process begins, so owners see only well-backed, well-run partners. Private equity acquisition demand remains high while premium practice supply is low in 2026, which can create favorable conditions for well-positioned sellers who enter the market with a structured, competitive process rather than a single unsolicited offer.
The goal of this phase is not simply to find a buyer. The goal is to create competition that pushes price up, improves terms, and gives the owner negotiating leverage that is difficult to create alone.
Step 5: Protecting Value During Diligence
After a letter of intent (LOI) is signed, typically granting the buyer a 30–90 day exclusivity window for due diligence in dental practice sales, the transaction enters its most fragile phase. This is where deals most commonly re-trade on price. Multiple compression can occur when diligence surprises emerge in an unrepresented sale.
Quality of Earnings Defense
On DSO transactions, McLerran provides dedicated Quality of Earnings (QoE) defense. In this process, the firm actively defends the EBITDA it underwrote when the buyer’s QoE team scrutinizes the financials. Because McLerran’s valuation is built to diligence-grade standards from the outset, the numbers tend to hold. If a buyer attempts to re-trade the agreed value, McLerran reminds them, firmly and professionally, that other vetted bidders remain available.
This advocacy can be one of the main factors behind McLerran’s approximately 85–90% transaction rate, compared to an industry norm closer to 35–40% and a do-it-yourself close rate of about 15–20%. Dental practices that complete structured preparation and enter diligence with organized financials typically achieve 90%+ close rates versus 65% for unprepared practices.
Learn how diligence-grade preparation can protect your deal by speaking with McLerran & Associates.
Step 6: Managing Staff and Patient Communication
Goodwill, the expectation that patients will continue returning after a sale, accounts for 60–85% of the total purchase price in most dental practice acquisitions. Protecting that goodwill requires careful, sequenced communication with staff and patients at the right moment in the process.
Most transition advisors recommend disclosing a practice sale to staff only after a letter of intent is signed and due diligence is underway, because premature disclosure can cause anxiety, turnover, and patient attrition. Well-managed transitions average less than 10% patient attrition within 18 months of closing, while poorly managed ones can reach 20–30%+ patient loss in the same period.
McLerran serves as the buffer between seller and buyer throughout this phase, protecting staff relationships and practice goodwill while managing the communication timeline. For owners whose core concern is the welfare of the patients and team they are leaving behind, this phase can be where professional sell-side representation delivers some of its most tangible value.
Step 7: Planning Post-Close Life and Equity
The structure of post-close life differs significantly between the two paths. In a doctor-to-doctor walk-away sale, the seller typically works back about 4–8 weeks to introduce patients to the new owner and support operational continuity before exiting. In a partnership or vest-out structure, the seller remains as a partner while the buyer acquires the remaining ownership interest over time.
In a private equity affiliation, a minimum 5-year post-close employment term is now required more consistently by private equity buyers, with the seller practicing under production-based compensation. Up to about 40% of the total deal value may be paid in equity rather than cash, held at either the joint-venture level with distributions or the holding-company level with higher potential upside but no distributions. McLerran helps owners model the real after-tax value of each structure across multiple time horizons so the equity component is sized and understood as an investment, not an afterthought.
Practices implementing a structured transition plan are significantly more likely to achieve their first-year revenue goals, which reinforces that post-close integration is a phase to plan for, not improvise.
Conclusion: Using the Seven Phases to Guide Your Transition
A dental partnership transition or sale follows seven predictable phases: pre-planning valuation, deal-team assembly, path comparison, confidential marketing, diligence defense, staff and patient communication, and post-close integration. Owners who engage a dental-only sell-side advisor and advocate at the start of this sequence can shape the narrative around their EBITDA, create competition, and often achieve about 30% higher outcomes with an 85–90% close rate. With the track record described earlier and more than $2 billion in transaction volume, McLerran & Associates is a dental-specific sell-side advisor built to guide premier practice owners through every phase.
Schedule a free, confidential discovery call with McLerran & Associates today.
Frequently Asked Questions
How long does a dental partnership transition or practice sale typically take from start to finish?
The timeline depends primarily on which path the owner pursues. A doctor-to-doctor sale, including a walk-away sale or a partnership vest-out, can move from listing to close in 60–120 days when managed by an experienced advisor. A DSO or private equity affiliation typically runs 3-6 months of active process from engagement to close because institutional buyers conduct multi-layer due diligence, negotiate complex multi-document transaction packages, and require equity rollover documentation.
Owners who begin preparation 2 to 3 years before their target sale date, organizing financials, addressing deferred maintenance, and reducing owner dependency, tend to move through the process faster and at higher valuations than those who start late. McLerran & Associates recommends beginning the valuation conversation well before any firm decision to sell, because the preparation phase can directly shape the outcome.
What is the difference between a Quality of Earnings review and a standard practice valuation?
A standard practice valuation estimates what a practice may be worth by analyzing revenue, profitability, and market comparables. A Quality of Earnings (QoE) review is a deeper, buyer-commissioned audit that scrutinizes the specific line items behind the EBITDA figure, examining whether add-backs are legitimate and sustainable. Add-backs are expenses removed from the income statement to reflect true profitability, such as above-market owner compensation or personal expenses run through the business.
In a DSO transaction, the buyer’s QoE team will often attempt to challenge every add-back and compress the EBITDA figure, which directly reduces the purchase price if the seller cannot defend the numbers. McLerran & Associates builds its valuations to diligence-grade standards from the outset, so the EBITDA figure is more likely to hold up when the buyer’s QoE team scrutinizes it, which can help prevent the deal from being re-traded at a lower price after the letter of intent is signed.
How does McLerran & Associates create competition among buyers, and why does it matter?
Creating competition means running a structured, auction-like process in which multiple qualified buyers submit offers simultaneously rather than allowing a single buyer to negotiate without pressure. McLerran builds a vetted pool of well-qualified buyers. For DSO transactions, this typically generates around 10 offers within a 45 to 60-day bid window, and the firm has blacklisted DSOs known for poor post-close environments so that only well-backed, well-run partners reach the table.
Competition matters because it can be the primary mechanism that moves price and improves terms. An owner negotiating directly with a single DSO has limited leverage, because that buyer knows it is the only option and bids accordingly. When multiple buyers know they are competing, they sharpen their offers on price, cash at close, equity structure, earnout terms, and clinical autonomy. McLerran’s process, which produces approximately 30% higher valuations on average compared to owners selling without representation, can represent a meaningful difference on a premier practice.
Should I tell my staff I am planning to sell the practice?
Timing staff communication is one of the most sensitive decisions in the entire transition process, and getting it wrong can directly reduce the value of the practice. Premature disclosure, before a letter of intent is signed and due diligence is underway, can create anxiety among team members, trigger voluntary departures, and cause patient attrition, all of which erode the goodwill that accounts for a significant portion of the practice’s purchase price.
The standard recommendation among experienced transition advisors is to wait until the LOI is signed before informing staff and to frame the communication carefully around continuity and the buyer’s commitment to the team. McLerran & Associates manages this communication timeline as part of its sell-side advocacy, serving as a buffer between seller and buyer to protect staff relationships and practice goodwill through the close.
Is now a good time to sell a dental practice?
Market conditions as of mid-2026 remain favorable for many owners of premier, well-run practices. Private equity acquisition demand is high while the supply of high-quality practices is relatively constrained, a combination that can support strong valuations for well-positioned sellers. The largest retirement-age cohort in dentistry is approaching transition, and many active private equity buyers anticipate completing a recapitalization within the next 12 to 36 months, which can give sellers who go to market now added leverage with buyers preparing for those events.
At the same time, valuations are expected by some observers to compress over time as the industry matures, and some private equity groups have faced financial restructuring challenges, which underscores the importance of vetting buyers carefully. McLerran & Associates will provide an honest assessment of how a specific practice is positioned in the current market, and if the timing does not appear right, the firm can update the valuation at no charge a year later rather than push an owner into a deal that may not serve them.
